Navigation Links
Immunotherapy Offers New Hope for Cancer Patients: One Man’s Alternative Cancer Treatment Journey
Date:12/23/2013

Simpsonville, SC (PRWEB) December 23, 2013

It started as a mole on his leg, and spread quickly, despite aggressive chemotherapy and surgery. When 59-year-old Ray Merrill learned his melanoma was incurable and amputation of his leg was the only option available to buy just a little more time, he prayed for another solution. The alternative cancer treatment he found at Perseus PCI earlier this fall was literally the answer to his prayers, keeping his limb intact while bringing him immediate relief from pain, and in December, an extensive imaging test showed came back clear, showing no evidence of disease.

“My oncologist couldn’t believe it!” marvels Merrill. “Just a few months ago, I was headed straight to Stage 4 melanoma, with nothing but pain in the future. I was devastated, thinking I had no chance to see my 14-year-old daughter grow up.”

After receiving his ‘incurable’ diagnosis this fall, Merrill was determined not to spend whatever time he had left undergoing toxic chemotherapy regimens, or being bedridden after major surgery. Through his own extensive research and outreach, he learned of the Perseus PCI cancer vaccine.

“When I heard how it caused no side effects, I thought it was almost too easy to be real,” remembers Merrill. “Many people agreed with that conclusion and tried to talk me out of it, but I felt that this option was absolutely what I needed to do – it made sense and I was determined to try it. Hearing Dr. Wagner speak lifted my spirits and gave me hope, knowing there was a chance to beat this.”

Four months later, after completing the series of monthly inoculations, the soft-spoken Georgian native is certain his decision was the right, life-affirming one. From first to final treatment, all went smoothly, exactly as planned, and the most recent, completely
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)
2. Cancer Immunotherapy Expert Joins Pacific Meso Center Research Team
3. UroToday Launches New Prostate Cancer Focused Content Including Immunotherapy for Metastatic Castration-resistant Patients
4. Tuberculosis Immunotherapy Grant for Immunoxel Honibe Honey Lozenges
5. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
6. FDA Review in Journal for ImmunoTherapy of Cancer Offers New Insights into Cancer Immunotherapy Product Development & Clinical Evaluation
7. Argos Therapeutics Presents Data Showing Memory T Cell Expansion After Administration of Fully Personalized Immunotherapy Correlates with Overall Survival Benefit in Patients with Metastatic Renal Cell Carcinoma
8. Leading Cancer Research Centers Team Up To Launch Biotech Startup Focused On Cancer Immunotherapy
9. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
10. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
11. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... April 23, 2015  Veracyte, Inc. (NASDAQ: VCYT ) ... agreement to sell approximately $40 million of its common ... investors will purchase an aggregate of 4,907,975 shares of ... share, the closing stock price on April 22, 2015. ... investors, including Broadfin Capital, Camber Capital, Deerfield, Longwood Capital ...
(Date:4/23/2015)... Irvine, CA (PRWEB) April 23, 2015 ... research leader in Personalized Medicine, is excited to ... Medication Response profile . This profile assesses 62 ... and provide dosing information for commonly prescribed non-opioid ... gabapentin (brand name Neurontin), alprazolam (brand name Xanax) ...
(Date:4/23/2015)... YORK, NY , April 23, 2015 /PRNewswire/ - ... issued an Executive Informational Overview ® (EIO) on ... full 52-page report is available on Crystal Research Associates, ... as on Aeterna Zentaris, website at www.aezsinc.com . ... transitioning into a specialty biopharmaceutical company in oncology, endocrinology, ...
(Date:4/22/2015)... , April 23, 2015  The Heinz Family ... th Heinz Awards, which will present unrestricted ... Americans for their creativity and determination in finding ... This year,s recipients include a prolific ... modern-day life and personal relationships; two former Marines ...
Breaking Biology Technology:Veracyte, Inc. Announces $40 Million Private Placement 2Veracyte, Inc. Announces $40 Million Private Placement 3Veracyte, Inc. Announces $40 Million Private Placement 4Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 2Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc. 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 2From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 3From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 4From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 5From a Scientist Who Develops Human Microlivers to a New Yorker Cartoonist Who Masterfully Depicts the Humor and Heartbreak of Everyday Life: The 20th Heinz Awards Honors Six Changemakers 6
... Scientists engaged in biological research and drug discovery are ... BioInformatics, LLC ( www.gene2drug.com ), the premier research ... released preliminary data from the company,s newest report ... Science Suppliers. In this report, we set out ...
... LOUIS, Feb. 11 Sigma-Aldrich, a leading Life,Science and High ... by 6% to $0.68 from $0.64 in the same quarter ... $510 million in the fourth quarter 2008 declined by 4%,compared ... fourth,quarter grew 3% from a year ago. Fourth quarter organic ...
... Development for Chronic Pain IndicationsLA JOLLA, Calif., Feb. ... TPTX ) today announced that oral administration of ... and well-tolerated in healthy male and female subjects ... successful completion of this Phase I trial demonstrating ...
Cached Biology Technology:Life Science Labs Reacting to the Economic Crisis 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 3Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 4Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 5Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 6Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 7Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 8Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 9Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 10Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 11Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 12Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 13First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore ... key protein linked to stem cell-like behavior in terminal-stage ... drugs that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , ...
... to reduce by more than half the time it takes ... researchers in Penn State,s College of Agricultural Sciences. The finding ... foodborne illness, allowing epidemiological investigators to identify the exact strains ... more quickly find -- and eliminate -- the source of ...
... long been used for various purposes, like cleaning wastewater at ... handcrafted wickerwork, as means of nutrition and, in traditional medicine, ... Fraunhofer Institute for Building Physics IBP in Valley now want ... to wit, for the insulation of outer walls or ...
Cached Biology News:Singapore research team identifies new drug target in deadly form of leukemia 2Researchers develop a faster method to identify Salmonella strains 2Researchers develop a faster method to identify Salmonella strains 3Using cattails for insulation 2Using cattails for insulation 3
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... cell lines in combination with the ... parameters. Nucleofector Kits are only functional ... Different cell lines can be transfected ... and viabilities are given in brackets ...
... BUF040A is a diluent that is designed ... antibodies which are paired with a mouse monoclonal ... contains rabbit and mouse proteins to prevent non-specific ... • This buffer may be ...
... your protein is in solution or in a ... mass spectrometry. Proteins will be digested to produce ... of the peptides are determined by MALDI-TOF, and ... peaks (peptides) from MALDI-TOF will be determined by ...
Biology Products: